SciTechSeries cordially invite a worldwide global audience and presenters to participate at the 2^nd Global Summit on Diabetes and Endocrinology as a Speaker/Delegate/YRF which is scheduled to be held in Chicago, USA during Feb 20^th to 21^st, 2024. The special interest and theme of the conference are "SWEET: Scrutinizing Worldwide Advances & Enhancing Endocrinology Treatments".

Global Summit on Diabetes & Endocrinology 2024 aims to provide an opportunity to share knowledge, expertise along with unparalleled networking opportunities between a large number of medical and industrial professionals in this sphere. The meeting gathers renowned scientists, endocrinologists, physicians, surgeons, young researchers, industrial delegates and talented student communities in the field of diabetic medicine under a single roof where networking and global partnering happens for the acceleration of future research. This conference is an international platform for presenting research about diabetes management and therapeutics, exchanging ideas about it and thus, contributes to the dissemination of knowledge in management of the disease for the benefit of the society.

Why Attend DIABETES-2024 Conference?

Medical doctors and health care providers consider the prevention of Endocrinology and metabolic disorders as an essential tool to improve the general health status of the population. Diabetic and metabolic issues and as well as exploring new thoughts and ideas for the treatment of Endocrine Complications. It is a great opportunity to meet the world’s Diabetes, Obesity & Heart Experts. The proportion of people suffering from Endocrinology and metabolic disorders is expected to increase in the future according to a recent statistical survey. Best platform for Global business and networking opportunities.

Our Vision

"We aim to bring the research and innovations happening around the world to facilitate interaction, knowledge sharing, and exchange." We also hope to inspire university professors, students, researchers, clinicians, and entrepreneurs from a variety of fields, including but not limited to clinical, medical, business, technology, healthcare, and pharmaceutical. Through scientific gatherings and deliberations, we hope to bring advancements in science and technology to humanity. We believe in introducing novel methods and techniques in science, business, and technology to provide a better understanding of the developments."

Benefits of Attending our Conference:                   

• Get publication of your abstract with DOI

• Young Scientist Award recognition certificate and memento to the winners

• Be acquainted with the modern-day improvements and demanding situations inside your industry

• Our conferences provide best Platform for your research through oral presentations.

• Learn about career improvement with all the latest technologies.

• Young Scientists will get appropriate and timely information by this Forum.

• Platform for collaboration among young researchers for better development.

• Provide an opportunity for research interaction and established senior investigators across the globe in the field of Diabetes

• Share the ideas with both eminent researchers and mentors.

• It’s a great privilege for young researchers to learn about the research areas for expanding their research knowledge and increase participation

• Great resource for learning new career skills.

• Global exposure to your research

Past Conference Details

The previous series of Diabetes & Medicare Expo 2023 was held at Chicago, USA on May 25-26, 2023 based on the specific theme of “Recent Advancements and Developments in Diabetes” captures the collaborative spirit of the Conference which will be both a scientific and educational event.

The Conference offered unique opportunities for participants led to the international collaborations, exchange knowledge and experience in the prevention of healthcare associated infections and control of diseases around the World. The most resonating topics will be addressed including quality of patient care, advanced methods in hospitals epidemiology research and early results of major clinical trials in the field, improving prevention strategies using various implementation tools as well as social media, telemedicine, and simulation models.

Market Analysis

• Diabetes & Endocrinology 2024 Conference invites all Academic Scientists, Leading Endocrinologists, Surgeons, Oncologists, Radiation Therapists, General Physicians, Dieticians, Primary Health care specialists, Internists, Pharmaceutical Industrial Delegates, talented young scientists, and student communities across the globe to attend Diabetes conference under a single roof where networking and global partnering happens for the acceleration of future research.

Today’s Market Study of Diabetes in USA | Europe | Middle East | Asia Pacific

• Europe: The number of people living with diabetes in Europe is expected to increase from 52 million in 2014 to 68.9 million by 2035, according to the International Diabetes Federation (IDF). Across Europe, around 1 in 11 adults is affected and this number is set to rise as the population ages.

• USA: Diabetes Mellitus has been growing at an exponential rate and World Health Organization (WHO) estimates that the diabetic population is likely to reach 366 million in 2030. The United States is expected to have an increase of 102 per cent in the diabetic epidemic in 2030 when compared to 2000

• Middle East: The rate of diabetes in parts of the Arabian Peninsula is over twice the global average rate, and much higher than some other areas of the Middle East and North Africa (MENA). And cases of type-2 diabetes outnumber cases of type-1 diabetes by a ratio of 10:1

• Asia Pacific: The Asia-Pacific Diabetes Care Devices Market has been estimated at USD 2.461 Billion in 2015 and is projected to reach USD 3.518 billion by 2020, at a CAGR of 7.41% during the forecast period from 2015 to 2020

• Type 1 diabetes is caused by an autoimmune reaction in which the body’s immune system attacks the insulin-producing beta cells of the pancreas. As a result, the body produces very little or no insulin.

• Type 2 diabetes is the most common type of diabetes. Initially, hyperglycaemia (high blood glucose levels) is the result of the inability of the body’s cells to respond fully to insulin, a situation termed ‘insulin resistance’.

• Gestational diabetes (GDM) is characterized by high blood glucose levels during pregnancy. It may occur at any time during pregnancy.  Women who experience GDM face an increased risk of developing type 2 diabetes later in life. In addition, babies born to mothers with GDM also have a higher lifetime risk of obesity and developing type 2 diabetes themselves. This contributes to an intergenerational cycle of obesity and diabetes that seriously impacts the health of the entire population, and the generations to come.

• Impaired glucose tolerance (IGT) is a condition of raised blood glucose levels above the normal range, but below the recommended diabetes diagnostic threshold. The terms ‘prediabetes’ and ‘non-diabetic hyperglycaemia’ are sometimes used as alternatives.

• IGT is important because it:

• Insulin: Launch of generic versions of insulin and extensively growing demand for novel insulin in controlling the blood sugar levels in both type 1 and type 2 diabetes ate factors anticipated to fuel the growth of insulin segment in the market during the forecast period.  In march 2019 Eli Lilly (key player) and company launched Lispro, a generic version of rapid-acting Humalog insulin which shall be available in the US by making it more accessible for diabetic patients. 

• Diabetes increases the risk of early death: Approximately 4.2 million adults will die as a result of diabetes and its complications in 2019. This is equivalent to one death every eight seconds. Globally, 11.3% of deaths are due to diabetes. Almost half of these deaths are in people under 60 years of age. Half of the 463 million adults living with diabetes today are unaware that they have the condition, and are therefore at high risk of developing serious diabetes related complications.

Age profile of diabetes

Working age (20-64) 72.0% three in four people living with diabetes (352 million people) are of working age (between 20 and 64 years old). This number is expected to increase to 417 million by 2030 and to 486 million by 2045.

Older people (65+) 27.8% in 2019, the estimated number of people over 65 years of age with diabetes is 111 million. One in five adults in this age group is estimated to have diabetes. It is projected that by 2030 the number of people over 65 with diabetes will further increase to 195 million. By 2045, it will reach 276 million.

Children and adolescents (0–19) 0.2% an estimated 1.1 million children and adolescents (aged under 20) have type 1 diabetes. There is some evidence that type 2 diabetes among children and adolescents is increasing in some countries.

Countries with the highest numbers of people with diabetes (2021) In 2021, the countries with the largest numbers of adults with diabetes are China, India and the United States of America, and are anticipated to remain so until 2030. It is projected that the number of people with diabetes in Pakistan will exceed that in the United States of America by 2045, moving the country to third place.

Low- and middle-income countries: The highest prevalence of diabetes in adults occurs in high-income countries, with an estimated 10.4% of the population having diabetes. The diabetes prevalence is 4% in low-income countries, and 9.5% in middle-income countries.

The Highly exciting 2^nd Global Summit on Diabetes and Endocrinology (Diabetes Conference 2024) is intended to be a forum for conversation and networking place for Academics, Researchers, Doctors, Physicians, Surgeons, Endocrinologists, Professionals, Researchers, Administrators, Educational leaders, Industry experts and Business leaders.

Diabetes Conference 2024 highlights the theme "SWEET: Scrutinizing Worldwide Advances & Enhancing Endocrinology Treatments" which emphasis on the latest advancements in prevention and treatment cure of various metabolic diseases which may be thanks to diabetic and endocrine complications and provides robust discussions on methods and methods associated with diagnosis, prevention and management of metabolic disorders also as explore new ideas and concepts for treatment of Diabetes.